Accretion Pharmaceuticals (NSE:ACCPL) Total Operating Expense: ₹107.3 Mil (TTM As of Mar. 2026)


NSE:ACCPL Accretion Pharmaceuticals Ltd NSE:ACCPL
18 GF Score
Price ₹153.60
! 6 Warning Signs
View Full Analysis

What is Accretion Pharmaceuticals Total Operating Expense?

Accretion Pharmaceuticals NSE:ACCPL -0.26% 18 Total Operating Expense is ₹107.3 Mil as of Mar. 2026. GuruFocus rates NSE:ACCPL with a GF Score™ of 18/100. The stock has 6 warning signs investors should review.

Accretion Pharmaceuticals's Total Operating Expense for the six months ended in Mar. 2026 was ₹58.2 Mil. Accretion Pharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was ₹107.3 Mil.

Accretion Pharmaceuticals Total Operating Expense Related Terms

Accretion Pharmaceuticals Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Accretion Pharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accretion Pharmaceuticals Total Operating Expense Chart

Accretion Pharmaceuticals Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Total Operating Expense
39.03 49.67 54.00 63.60 107.34

Accretion Pharmaceuticals Semi-Annual Data
Mar22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Operating Expense Get a 7-Day Free Trial 0.00 26.11 37.50 49.11 58.23
NSE:ACCPL
18GF Score
Accretion Pharmaceuticals Ltd NSE:ACCPL
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Accretion Pharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹107.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of ₹107.3 Mil mean?
Accretion Pharmaceuticals (NSE:ACCPL) has a Total Operating Expense of ₹107.3 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Accretion Pharmaceuticals and its competitors.
Is Accretion Pharmaceuticals' Total Operating Expense too high?
Accretion Pharmaceuticals' current Total Operating Expense is ₹107.3 Mil. Overall, Accretion Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' Total Operating Expense compare to LLY and JNJ?
Accretion Pharmaceuticals' Total Operating Expense of ₹107.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Accretion Pharmaceuticals and its competitors. Accretion Pharmaceuticals's current Total Operating Expense is ₹107.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current Total Operating Expense of ₹107.3 Mil. The current Total Operating Expense is ₹107.3 Mil. Accretion Pharmaceuticals' overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current Total Operating Expense is ₹107.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Accretion Pharmaceuticals Business Description

Address 29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, Vasna-Chacharwadi, Ta - Sanand District, Ahmedabad, GJ, IND, 382213
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
18GF Score

Get the complete analysis for NSE:ACCPL

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹153.60
Price